Login to Your Account



Other news to note


Friday, February 28, 2014

Basilea Pharmaceutica Ltd., of Basel, Switzerland, said the FDA designated isavuconazole as a qualified infectious disease product for the treatment of invasive mucormycosis, a life-threatening invasive fungal infection caused by certain emerging molds.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription